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Abstract
Summary The study explores osteoporosis medication prescribing across Canadian provinces and any impact on hip
fracture rates. Despite a marked variation in the prescribing
of such medication, there is no effect on the hip fracture rate
in either gender or any age group, suggesting either poor
targeting or lack of efficacy.
Introduction Hip fractures are the most disabling and costly
of osteoporotic fractures, and a reduction in the risk of hip
fracture is an expectation of osteoporosis medications. In this
study, we have compared the use of osteoporosis medication
across Canadian provinces with the rate of hip fractures in
the same regions.
Methods Three years of hip fracture data (2007–2009 inclusive) were obtained from the Canadian Institute for Health
Information for all Canadian provinces excluding Quebec.
Population information was obtained from Statistics Canada
and medication information from the Brogan Inc. database.
Because osteoporosis medication is available daily, weekly,

monthly, and yearly, medication prescriptions were converted
to “units” of prescribing, so that a once a year infusion represented 365 units, a monthly prescription 30 units, and so forth.
Results There is a fourfold difference in prescribing across
provinces but no corresponding variation in hip fracture rate.
No significant correlation exists between prescribing load and
hip fracture rate. This was true for all age groups, both genders,
and for both intertrochanteric and subcapital hip fracture.
Conclusions We find no association between osteoporosis
medication prescribing and hip fracture rate. Possible explanations include insufficient numbers of at-risk patients on
treatment, inappropriate targeting, and either lack of efficacy
or efficacy limited to only certain subgroups of patients such
as those with demonstrable trabecular osteoporosis.
Keywords Hip fracture . Medication . Osteoporosis .
Prescription rates
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It is an expectation of osteoporosis medications that they
reduce non-vertebral fractures as well as vertebral fractures.
The various randomized controlled trials conducted have
demonstrated that the antiresorptive agents, the mainstay of
osteoporosis treatment, can produce a marked reduction in
subsequent vertebral fractures and a much more modest reduction in non-vertebral fractures [1]. From the economic
perspective, reduction in hip fractures is particularly desirable
and has been shown in some studies but not so clearly in
others [1]. In most cases, the studies were primarily designed
to reduce vertebral fractures. Patients were therefore selected
on the basis of spinal osteoporosis, as shown either by low
spine density, spinal fractures, or both. In addition to a reduction in vertebral fractures, a reduction in hip fractures was also
seen with treatment. Where selection was on the basis of hip
cortical bone density, with or without vertebral fractures, a
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reduction in both vertebral and non-vertebral fractures was
seen. However, if spinal fractures were not present, the benefits in terms of hip fracture reduction were more variable
[2–4]. Generally, the benefit of treating patients with a femoral
neck T-score of better than −2.5 is minimal [4].
Approaching the problem from the direction of the hip
fracture patient and asking how common osteoporosis actually is in these patients, it is found that although hip bone
density predicts future fracture risk, most hip fracture patients do not, in fact, have particularly thin bones compared
to their peers [5, 6]. In our series of hip fracture patients, a
minority has a bone density that would be considered low.
Thus, only 40 % of women and few men fall below a femoral
neck T-score of −2.5 [7]. Similar findings have been reported
by Stone et al. in 2003 [8] and Siris et al. in their 2004 study
[9] where only 6.4 % fell below this threshold on peripheral
bone density measurements. The main problem is that most
fractures occur in people who are not at particularly high
risk, but because of the great numbers of such people, they
contribute most of the fractures. Thus, identification of these
people prior to fracture is virtually impossible and indeed the
benefit of treating such people is dubious. Even when they
have identified themselves by having one hip fracture, prevention of the second hip fracture has proven difficult, presumably because many of the fractured patients are not from
the high-risk population [3]. It seems therefore that while
such treatment may benefit selected individuals with low
bone mass, the impact of this at the population level is less
clear and may be insufficient to make a discernable reduction
in hip fracture rates.
Studies of the changing rate of hip fracture over the past
decades have shown a decline over the years and, while in
recent decades there has been a rise in osteoporosis prescription rates, a causal association cannot be presumed. Thus in
the study of change in hip fracture rate in Canada over the
years from 1985 to 2010, while showing a steady decline
over the decades and an increasing rate of decline after 1996,
it was felt that this increasing rate of decline began before the
use of bisphosphonates was sufficiently widespread to be the
cause [10]. Interestingly, a similar finding was seen in the
Netherlands with a break in the line at around 1994, while in
Spain, a marked increase in prescribing produced no decrease in the hip fracture incidence [11, 12]. In this study,
we have explored this issue further. We have compared the
use of osteoporosis medication across the provinces of Canada, which varies widely, with the concurrent rate of hip
fracture to see if higher prescription rates in certain provinces
were associated with lower fracture rates. We have also done
this with the intertrochanteric and subcapital fractures separately to see if there is any differential effect on the two
fracture types, as there is evidence that the intertrochanteric
fracture may be the more trabecular osteoporotic hip fracture
for which the antiresorptives might be more effective [13].
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Materials and methods
This study examines osteoporosis medication prescribing
and hip fracture rate variation by province (excluding Quebec and the territories) in Canada between 2007 and 2009.
Data sources
The Canadian Institute for Health Information (CIHI) manages health and healthcare information. CIHI’s Discharge
Abstract Database (DAD) collects discharge statistics from
Canadian healthcare institutions by procedures and diagnoses, including administrative, clinical, and demographic information. The province of Quebec does not contribute to
this database and so is not included in our study. Hip fracture
data were obtained from CIHI which also provided information on physician numbers across the provinces. Brogan Inc.
collates prescription numbers from pharmacies across Canada, including prescriptions funded by private drug plans and
the provincial (public) drug plans. The information available
includes a measure of the amount of medication dispensed,
as prescriptions as such can be written for a variable length of
time. The data are collected within a forward sortation area
(FSA), this being the geographic region used by Canada
Post. And for this study, all FSAs within each province have
been amalgamated to obtain prescribing loads per province.
The FSA is the region containing the pharmacy dispensing
the medication and not that of either the physician or the
patient. The assumption is that the prescription is filled close
to the home of the patient, which for larger geographic areas
and certainly at the provincial level, is almost certainly the
case given that healthcare and for the senior population the
medication formularies are funded at a provincial level.
Population information was obtained from Statistics Canada
2006 census data and is also available by FSA regions.
Measures
All hospitalization records from 2007 to 2009, in which the
most responsible diagnosis was a hip fracture, were obtained
from the CIHI DAD and identified using the Canadian
Classification of Health Interventions [CCI] and the International Classification of Diseases 10th Revision, Canada
[ICD-10-CA]. Hip fractures were identified from the ICD10-CA using diagnosis code S72.0-.2 and from the CCI
using diagnosis codes 1VC74LANW, 1VA53LAPMN, and
1GZ31CAND. Total annual hip fractures were calculated for
the study period (2007–2009) and stratified by age group,
sex, and province (initially 5-year intervals with aggregation:
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, and ≥85 years).
It is unclear whether readmission for hip fracture was the
result of original hip fracture complications, inter-hospital
transfers, or due to a second hip fracture; therefore, all hip
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fracture hospitalizations were counted. Because osteoporosis
medication is available daily, weekly, monthly, and yearly,
medication dispensing units were converted to days of prescribing, so that a once a year infusion prescription (zoledronic acid) represented 365 days, a prescription for a medication taken monthly (risedronate) represented 30 days of
treatment, and so forth. The number of days of prescribing
of the osteoporosis medications is summed to provide a
measure of the prescribing load for the region and time under
consideration. The medications included in the analysis are
hormone replacement therapy, risedronate, alendronate, zoledronic acid, didronel, raloxifene, and teriparatide. For the
time studied, denosumab was not yet available
The denominator was generated using population data
obtained from the 2006 census for each province excluding
Quebec. In addition, territories including the Northwest,
Yukon, and Nunavut were excluded from this analysis due
to their relatively low population base (responsible for .25 %
of the overall Canadian population).
Study population
The database contained a total of 65,659 hip fracture episodes, 18,316 (28 %) in men (average age 78.48±10.90) and
47,343 (72 %) in women (average age 82.08±9.63). Of the
total hip fractures, less than 1 % was disregarded because of
missing or incorrect postal code information.
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Osteoporosis Canada website for details (www.osteoporosis.ca/
index.php/ci_id/5521/la_id/1.htm), but quite different rates of
prescribing, by a factor of almost 4. It is not explained by a
difference in family physician density (or availability) as this
differs little across the provinces, although information about
specialists who may have an interest in osteoporosis is not
available [14]. Figure 2 also shows the rate of hip fracture
across the provinces in the same order for both men and
women. There is little difference and clearly no relationship to
prescribing load.
Our prescribing data do not provide the age breakdown
of the patients for whom the prescriptions are written. It is
possible that the impact is on the younger patients and
women who may be more likely to be treated. Accordingly we have looked at the hip fracture rate across
provinces for different age groups and the separate genders. Again, no relationship between prescribing rate and
hip fracture rate emerged. We repeated each of these
analyses for the subcapital and intertrochanteric fractures
separately but no impact on either was apparent. As an
example, Fig. 3 shows proportion of IT fractures in females by province, and again, no effect is apparent. We
also noted a reduction in prescribing across the 3 years of
the study with a decline of 15.4 % across the 3 years. This
is seen in all provinces, but is not associated with any rise
in fracture rate.

Statistical analysis

Discussion

The denominator was derived using provincial census population data from 2006; hip fracture occurrences and prescribing load were aggregated for the years 2007–2009, by
province, gender, and age group and then used to calculate
the annual unadjusted (crude) fracture rate. Hip fracture rates
were standardized per 10,000 person-years and calculated
for the population over the age of 54 for each province. Rates
were adjusted to the 1991 age structure of the Canadian
population using the direct method. Hip fracture rates were
analyzed by province for each age group and gender against
the osteoporosis medication prescribing load and number of
physicians per province. The limited number of data points
makes correlation analysis unreliable so the analysis is largely descriptive.

We have been unable to demonstrate any impact of
osteoporosis medication on hip fracture rate across the
different provinces in Canada despite a wide variation
in prescribing rates. Although our data suffer from some
clear deficiencies, such as lack of information about the
age and gender of the patients receiving the medication,
it is surprising that no impact is even suggested across
age groups and either gender. Despite evidence at the
individual level that some benefit is to be expected, we
are not able to demonstrate this at the population level.
Prescribing does not, of course, confirm treatment and
the high rate of nonadherence with osteoporosis medication is well known but is likely mostly seen in failure
to fill the prescription, so such nonadherence would not
affect our results [15].
Targeting of patients for treatment may not be ideal, but as
the medications are likely to be prescribed for those with
poor bones shown, for example, by a low BMD, some
benefit in these patients may be expected. However, we
know that most hip fractures occur in patients who do not,
on BMD, have a high risk of fracture, and these may not have
been targeted for treatment prior to fracture. For example, in
our own exploration of hip fracture patients in our locality,

Results
Figure 1 shows the provinces ranked by prescribing load.
There is a substantial difference in prescribing habits across
the provinces. This appears to be due to a difference in practice
habit and not accessibility to provincial formularies. For
example, Alberta and Manitoba have similar formularies (see

Fig. 1 The number of
osteoporosis medication
treatment days per 10,000
population over 55 years across
the Canadian provinces for the
years 2006–2009. Sources:
Brogan Inc. (medication data)
and Statistics Canada
(population data)
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we found only about 30 % of women and very few men fell
into the CAROC high-risk zone on the basis of BMD alone
[16]. Thus, even with a widespread risk assessment program,
only about 25 % of the possible fracture cases might have
been treated, with an expected benefit of, at most, a 30 %
reduction. Thus, a maximum benefit of a 7.5 % reduction
might be the most that could be expected, and, as this would
be under ideal conditions of risk assessment, prescribing, and
compliance, the benefit may be much less. A recent report
[17] explored whether treatment reduces the risk of fracture
below that predicted by the FRAX tool [18]. This study
suggested an effect only in the highest risk group treated
for over 5 years and who show high compliance. Although
the authors hypothesize reasons why this does not indicate a
failure of efficacy in most treated patients, this would certainly be one and perhaps the simplest explanation. The
high-risk patients seem to constitute only 8.5 % of the

Fig. 2 Unadjusted crude rates
by province per 10,000
person-years of hip fracture by
gender (2007 to 2009)

population being treated and show an observed/predicted
ratio of 61 %. Again, given that even for high-risk patients’
treatment is often not provided, it seems likely that this
would make little impact at the population level. We have
no information regarding the reasons for the prescribing of
the osteoporosis medication. Treated patients may be a mixture of those at risk because of prior fractures with others
deemed to be at risk for other reasons. This may all point to
the need for better targeting, focusing only on those with
clear trabecular osteoporosis who closely resemble those in
the original studies. Clearly, a proper ad hoc prospective
longitudinal cohort study will be required in order to clearly
delineate the patients appropriate for treatment with these
medications.
It may be asked if there has been time for the effect to be
seen. In most studies, a reduction in hip fracture can be
shown within 3 years and sometimes much sooner. The
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Fig. 3 Unadjusted crude
rates by province per 10,000
person-years of female
intertrochanteric fracture (2007
to 2009)
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bisphosphonates have been in the market for over 10 years
and certainly for more than 3 years prior to our study, so it
seems unlikely that this is the explanation.
We have treated all osteoporosis medications as being
equal. The vast majority of prescriptions are for the
aminobisphosphonates, varying only in frequency (and
dose) of administration. Medication may be given daily,
weekly, monthly, or yearly and use of “days of treatment”
corrects for this disparity. All the aminobisphosphonates
have been shown to have similar efficacy at least as far as
preventing hip fractures in the mostly osteoporotic patients
enrolled in the studies is concerned, so combining in this
manner would seem to be justified.
In addition, the rate of prescribing is declining with no
obvious effect on hip fracture rate. In this case, however, it
may take longer for a decline in prescribing to be reflected in
the rise in hip fracture rate.
Lack of efficacy for the most vulnerable segment of
the population is another possible explanation. Most hip
fractures occur in the elderly who have fallen. Reducing
falls may reduce the fracture rate in these people, such
as has been shown in the vitamin D studies [19]. We
lack evidence of efficacy of osteoporosis medication in
the elderly, the most at-risk segment of the population.
We know that a fall onto the greater trochanter will
produce sufficient force to fracture any hip and this is
the type of fall that characterizes the elderly person.
About 30 % of those over 65 fall each year and some
recurrently [20]. The limited effect of medication on hip
bone strength may be insignificant in this situation.
Interestingly, the one antiresorptive study to show benefit
in terms of hip fracture prevention in patients who were not
particularly osteoporotic in terms of trabecular bone status
was the denosumab study [21]. This showed a significant
40 % reduction in hip fracture but also a reduced number of
falls in the treated group which may have, at least in part, been
the mechanism of benefit.

It may be that expanding the use of these medications to a
larger segment of the population may not work as their efficacy in low-risk individuals is open to doubt. Additionally,
although the concept of fracture risk prediction and prevention
is currently fashionable, most of these fractures (about 80 %
[1]) are non-vertebral and better predicted by cortical bone
status. Therefore, the outcome of the current risk assessment
tools [16, 18] is that the focus is on the type of bone least
responsive to treatment with our current medications.
One remaining possibility is that there are two influences
at work: one being the attempt to prevent fractures by treatment and the other being the prescribing of medication in
response to the hip fracture. Clearly, these would work in
opposite directions and if of equal force may cancel each
other out. However, evidence would suggest that the prevention mode is much the greater influence and that the number
of people started on treatment because of a hip fracture is
small. Several studies have demonstrated the low rate of
osteoporosis treatment after a hip fracture [22, 23].

Conclusions
This study has shown a marked variability in the use of
osteoporosis medications across Canadian provinces. Regardless of the cause of this, we have been unable to show
any impact on the rate of hip fracture in the different provinces. Additionally, the prescribing appears to be declining
and this is again not associated with any change in the
fracture rate across our years of study. Possible explanations
include inappropriate targeting, insufficient penetration, or
lack of efficacy of the medications to impact what appears to
be largely a cortical bone problem.
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